MEK
Mitogen-activated protein kinase kinase; MAPKK; MAP2K
MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling.
In general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases.
MEK Isoform Specific Products
All Product Categories
-
MEK Related Products (256)
Related Products (256)
-
Antibodies (9)
-
MEK Isoform Comparison
-
Cobimetinib (Standard)
0 ImagesSynonyms: GDC-0973 (Standard); XL518 (Standard)Cobimetinib (Standard) is the analytical standard of Cobimetinib. This product is intended for research and analytical applications. Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.
-
Selumetinib (Standard)
0 ImagesSynonyms: AZD6244 (Standard); ARRY-142886 (Standard)Selumetinib (Standard) is the analytical standard of Selumetinib. This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
-
Methylnissolin-3-O-glucoside (Standard)
0 ImagesCat. No.: HY-N2473RCAS No.: 94367-42-7Methylnissolin-3-O-glucoside (Standard) is the analytical standard of Methylnissolin-3-O-glucoside (HY-N2473). This product is intended for research and analytical applications. Methylnissolin-3-O-glucoside is a flavonoid glycoside derivative of Methylnissolin (HY-N2484). Methylnissolin-3-O-glucoside is isolated from plants of the genus Astragalus (Leguminosae). Methylnissolin-3-O-glucoside effectively induces the expression of AKT/Nrf2 and its downstream target genes HO-1 and NQO1. Methylnissolin-3-O-glucoside inhibits TNF-α-induced phosphorylation of MEK and ERK. Methylnissolin-3-O-glucoside exhibits free radical scavenging activity. Methylnissolin-3-O-glucoside inhibits cell proliferation and cell migration. Methylnissolin-3-O-glucoside is used in research on esophageal squamous cell carcinoma.
-
SJ-C1044
0 ImagesSJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC50 values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2, TIE2, and CSF1R, with IC50 values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer.
-
Simetryn (Standard)
0 ImagesSimetryn (Standard) is the analytical standard of Simetryn (HY-B1853). This product is intended for research and analytical applications. Simetryn is a triazine herbicide that exerts teratogenicity. Simetryn inhibits photosynthesis by blocking electron transfer in the chloroplast photosystem II and activates the MEK/Erk signaling pathway. Simetryn triggers vascular and developmental abnormalities in zebrafish and tadpoles, suppresses proliferation, enhances apoptosis, and induces malformations. Simetryn serves as a tool to establish a zebrafish model for studying arteriovenous malformations and related pathogenesis. Simetryn controls paddy weeds and can be used for research on developmental and vascular disorders.
-
APS-2-79 (Standard)
0 ImagesAPS-2-79 (Standard) is the analytical standard of APS-2-79 (HY-100627). This product is intended for research and analytical applications. APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATPbiotin binding to KSR2 within the KSR2-MEK1 complexe with an IC50 of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.
-
Lixisenatide (Leu-13C6,15N) TFA
0 ImagesCat. No.: HY-P0119SLixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
-
Cefotetan (Standard)
0 ImagesCefotetan (Standard) is the analytical standard of Cefotetan. This product is intended for research and analytical applications. Cefotetan is a semisynthetic cephamycin antibiotic that exerts its bactericidal effects by inhibition of cell-wall synthesis.
-
Pipoxolan
0 ImagesCat. No.: HY-105854ACAS No.: 23744-24-3Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent and anticancer agent. Pipoxolan modulates PI3K/AKT signaling pathways, and reduces the levels of Ras/MEK/p-ERK, MMP-2 and MMP-9. Pipoxolan inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators. Pipoxolan induces ROS generation, endogenous mitochondrial Apoptosis, and G0/G1 cell cycle arrest. Pipoxolan reduces cerebral infarction size and inhibits intimal hyperplasia. Pipoxolan can be used in research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia and lung cancer.
-
N-Oxide Lidocaine-d10
0 ImagesCat. No.: HY-B0185SCAS No.: 851528-10-4N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
-
Flurbiprofen axetil (Standard)
0 ImagesCat. No.: HY-101481RCAS No.: 91503-79-6Flurbiprofen axetil (Standard) is the analytical standard of Flurbiprofen axetil. This product is intended for research and analytical applications. Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway.
-
Binimetinib-d4
0 ImagesCat. No.: HY-15202S3CAS No.: 2890696-60-1Synonyms: MEK162-d4; ARRY-162-d4; ARRY-438162-d4Binimetinib-d4 (MEK162-d4) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
-
5-O-Methylvisammioside (Standard)
0 ImagesCat. No.: HY-N0442RCAS No.: 84272-85-5Synonyms: 4'-O-β-D-Glucosyl-5-O-methylvisamminol (Standard)5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) (Standard) is the analytical standard of 5-O-Methylvisammioside. This product is intended for research and analytical applications. 5-O-Methylvisammioside is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
-
Selumetinib sulfate (Standard)
0 ImagesSynonyms: AZD6244 sulfate (Standard); ARRY-142886 sulfate (Standard)Selumetinib (sulfate) (Standard) is the analytical standard of Selumetinib (sulfate). This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
-
CI-1040 (Standard)
0 ImagesCat. No.: HY-50295RCAS No.: 212631-79-3Synonyms: PD 184352 (Standard)
-
PD-334581 (Standard)
0 ImagesCat. No.: HY-107619RCAS No.: 548756-68-9PD-334581 (Standard) is the analytical standard of PD-334581 (HY-107619). This product is intended for research and analytical applications. PD-334581 is a MEK1 inhibitor.
-
RO4987655 (Standard)
0 ImagesCat. No.: HY-14719RCAS No.: 874101-00-5Synonyms: CH4987655 (Standard)RO4987655 (Standard) is the analytical standard of RO4987655. This product is intended for research and analytical applications. RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM for inhibition of MEK1/MEK2.
-
Mirdametinib (Standard)
0 ImagesSynonyms: PD0325901 (Standard); PD325901 (Standard)Mirdametinib (Standard) is the analytical standard of Mirdametinib (HY-10254). This product is intended for research and analytical applications. Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.
-
JTP-70902
0 ImagesCat. No.: HY-126048CAS No.: 871696-49-0JTP-70902, a p15INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect.
-
Sorafenib tosylate (Standard)
0 ImagesSynonyms: Bay 43-9006 tosylate (Standard)Sorafenib (tosylate) (Standard) (Bay 43-9006 (tosylate) (Standard)) is the analytical standard of Sorafenib (tosylate) (HY-10201A). This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
